Article Versions Notes

Suominen MI, Knuuttila M, Schatz CA, Schlicker A, Vääräniemi J, Sjöholm B, Alhoniemi E, Haendler B, Mumberg D, Käkönen S-M, et al. Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International Journal of Molecular Sciences. 2023; 24(3):2189. https://doi.org/10.3390/ijms24032189

Suominen, Mari I., Matias Knuuttila, Christoph A. Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, and et al. 2023. "Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model" International Journal of Molecular Sciences 24, no. 3: 2189. https://doi.org/10.3390/ijms24032189

Suominen, M. I., Knuuttila, M., Schatz, C. A., Schlicker, A., Vääräniemi, J., Sjöholm, B., Alhoniemi, E., Haendler, B., Mumberg, D., Käkönen, S.-M., & Scholz, A. (2023). Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International Journal of Molecular Sciences, 24(3), 2189. https://doi.org/10.3390/ijms24032189